Q1 2026 AstraZeneca PLC Earnings Call Transcript
Key Points
- AstraZeneca PLC (AZN) reported an 8% increase in total revenue for Q1 2026, driven by strong demand for innovative medicines.
- The company achieved a 12% growth in operating profit, reflecting a focus on operating leverage.
- AstraZeneca PLC (AZN) secured 14 approvals in major regions across its diverse portfolio, showcasing the value of its medicines globally.
- The oncology segment saw a 16% increase in total revenues, with double-digit growth across all geographic segments.
- AstraZeneca PLC (AZN) announced positive results from four Phase 3 programs, reinforcing progress towards its 2030 ambition.
- Core EPS growth was limited to 5%, impacted by a low tax rate in the prior period.
- Biopharmaceuticals total revenue declined by 2%, with growth in key brands offset by headwinds from Brilinta, Farxiga, and roxadustat.
- Cash flow from operating activities decreased slightly to $3.4 billion due to large milestones received in Q1 2025.
- Net debt increased by around $2.5 billion, driven by a payment of the second FY 2025 interim dividend.
- The company anticipates core finance expenses to increase this year, driven by higher lease expenses and lower interest income.
Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome to AstraZeneca's Q1 2026 webinar for investors and analysts.
Before I hand over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.
Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements. Please carefully review the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
